Moderna, Inc. (MRNA)
231.35
-17.34
(-6.97%)
USD |
NASDAQ |
Nov 12, 16:00
230.51
-0.84
(-0.36%)
After-Hours: 06:39
Moderna Enterprise Value : 92.52B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 92.52B |
| November 11, 2026 | 99.53B |
| November 10, 2026 | 100.39B |
| November 09, 2026 | 107.73B |
| November 06, 2026 | 101.75B |
| November 05, 2026 | 96.61B |
| November 04, 2026 | 103.44B |
| November 03, 2026 | 91.35B |
| November 02, 2026 | 88.27B |
| October 30, 2026 | 88.63B |
| October 29, 2026 | 89.05B |
| October 28, 2026 | 85.58B |
| October 27, 2026 | 83.08B |
| October 26, 2026 | 79.39B |
| October 23, 2026 | 79.90B |
| October 22, 2026 | 80.92B |
| October 21, 2026 | 98.37B |
| October 20, 2026 | 96.86B |
| October 19, 2026 | 90.72B |
| October 16, 2026 | 87.13B |
| October 15, 2026 | 94.60B |
| October 14, 2026 | 90.48B |
| October 13, 2026 | 86.42B |
| October 12, 2026 | 85.41B |
| October 09, 2026 | 89.96B |
| Date | Value |
|---|---|
| October 08, 2026 | 78.65B |
| October 07, 2026 | 78.44B |
| October 06, 2026 | 74.79B |
| October 05, 2026 | 81.15B |
| October 02, 2026 | 75.82B |
| October 01, 2026 | 75.39B |
| September 30, 2026 | 76.86B |
| September 29, 2026 | 77.33B |
| September 28, 2026 | 74.86B |
| September 25, 2026 | 75.50B |
| September 24, 2026 | 73.88B |
| September 23, 2026 | 68.81B |
| September 22, 2026 | 68.99B |
| September 21, 2026 | 65.15B |
| September 18, 2026 | 57.61B |
| September 17, 2026 | 59.22B |
| September 16, 2026 | 54.25B |
| September 15, 2026 | 53.51B |
| September 14, 2026 | 54.68B |
| September 11, 2026 | 53.59B |
| September 10, 2026 | 50.66B |
| September 09, 2026 | 50.26B |
| September 08, 2026 | 52.14B |
| September 04, 2026 | 54.22B |
| September 03, 2026 | 55.55B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Revolution Medicines, Inc. | 35.70B |
| Vaxcyte, Inc. | 8.588B |
| Twist Bioscience Corp. | 7.085B |
| BioNTech SE | 5.828B |
| Vir Biotechnology, Inc. | 1.684B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 162.00M |
| Revenue (Quarterly) | 1.313B |
| Total Expenses (Quarterly) | 1.151B |
| EPS Diluted (Quarterly) | 0.3791 |
| Gross Profit Margin (Quarterly) | 70.60% |
| Profit Margin (Quarterly) | 12.34% |
| Earnings Yield | -3.07% |
| Normalized Earnings Yield | -3.066 |